CA2303483A1 - Sag: gene sensible a l'apoptose - Google Patents

Sag: gene sensible a l'apoptose Download PDF

Info

Publication number
CA2303483A1
CA2303483A1 CA002303483A CA2303483A CA2303483A1 CA 2303483 A1 CA2303483 A1 CA 2303483A1 CA 002303483 A CA002303483 A CA 002303483A CA 2303483 A CA2303483 A CA 2303483A CA 2303483 A1 CA2303483 A1 CA 2303483A1
Authority
CA
Canada
Prior art keywords
seq
sag
cells
cys
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002303483A
Other languages
English (en)
Inventor
Yi Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2303483A1 publication Critical patent/CA2303483A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Cette invention se rapporte à de nouveaux gènes et à des polypeptides dérivés de ces gènes codant une protéine sensible à l'oxydoréduction qui favorise la croissance cellulaire, protège les cellules contre l'apoptose, séquestre les radicaux d'oxygène et peut servir à inverser les phénotypes des tumeurs. Dans une tentative d'identifier un ou des gènes responsables de l'apoptose induite par 1,10-phénanthroline (OP) dans les cellules tumorales, nous avons utilisé la technique de présentation différentielle et cloné un gène induisible par OP, le SAG (gène sensible à l'apoptose). Le SAG code une nouvelle protéine sensible à l'oxydoréduction, se fixant à l'hème, à l'aide d'un domaine de protéines à doigt de zinc. La protéine de SAG se compose de 113 acides aminés, avec un poids moléculaire calculé de 12,7 kDa. Les recherches sur l'homologie des séquences ont révélé que le SAG est fortement conservé parmi les espèces, ce qui suggère son importance fonctionnelle. Cette suggestion est prouvée par la découverte selon laquelle la dislocation du SAG dans la levure est létale. Deux mutants de délétion du SAG ont été détectés dans des lignées cellulaires de cancer humain prenant naissance dans le colon et dans les testicules, ce qui suggère son possible rôle dans la carcinogenèse humaine. La surexpression de la protéine de SAG dans une lignée de carcinomes de colon humain, DLD1, et dans une lignée de neuroblastomes humains, SY5Y, protège les cellules contre l'apoptose induite par OP, par le zinc et par des ions de cuivre. En outre, la transfection de SAG anti-sens inhibe certains phénotypes de cellules tumorales dans les lignées de cellules humaines DLD1 et la micro-injection d'ARN de SAG stimule la croissance cellulaire. Nous proposons que la protéine de SAG soit une molécule de protection cellulaire fonctionnant comme un capteur d'oxydoréduction pour faire tampon aux dommages induits par des contraintes oxydatives, ainsi qu'un facteur de croissance destiné à stimuler la croissance cellulaire. La protéine de SAG peut être une cible moléculaire idéale dans l'élaboration de médicaments contre les maladies neurodégénératives, les cancers et les dystrophies musculaires, et pour favoriser la cicatrisation.
CA002303483A 1997-12-19 1998-12-15 Sag: gene sensible a l'apoptose Abandoned CA2303483A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6817997P 1997-12-19 1997-12-19
US60/068,179 1997-12-19
US9984098P 1998-09-11 1998-09-11
US60/099,840 1998-09-11
PCT/US1998/026705 WO1999032514A2 (fr) 1997-12-19 1998-12-15 Sag: gene sensible a l'apoptose

Publications (1)

Publication Number Publication Date
CA2303483A1 true CA2303483A1 (fr) 1999-07-01

Family

ID=26748669

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002303483A Abandoned CA2303483A1 (fr) 1997-12-19 1998-12-15 Sag: gene sensible a l'apoptose

Country Status (8)

Country Link
EP (1) EP1044217A2 (fr)
JP (1) JP2001526063A (fr)
KR (1) KR20010033299A (fr)
AU (1) AU765741B2 (fr)
BR (1) BR9813757A (fr)
CA (1) CA2303483A1 (fr)
NZ (1) NZ503417A (fr)
WO (1) WO1999032514A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078203B1 (en) 1999-03-31 2006-07-18 The University Of North Carolina At Chapel Hill Isolated DNA encoding cullin regulators ROC1 and ROC2, isolated proteins encoded by the same, and methods utilizing the same
AU779562B2 (en) * 1999-03-31 2005-01-27 University Of North Carolina At Chapel Hill, The Isolated DNA encoding cullin regulators ROC1 and ROC2, isolated proteins encoded by the same, and methods utilizing the same
AU2872501A (en) * 1999-12-21 2001-07-03 Eirx Therapeutics Limited Screening method
US6979551B2 (en) 2000-04-03 2005-12-27 Rigel Pharmaceuticals, Inc. Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents
US6740495B1 (en) 2000-04-03 2004-05-25 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay
ATE325889T1 (de) * 2000-07-07 2006-06-15 Eirx Therapeutics Ltd Screening-verfahren
NZ526101A (en) * 2000-12-22 2005-06-24 Janssen Pharmaceutica Nv Genes for drug target identification in yeast and fungi i.e. candida that are involved in apoptosis
CN115345122B (zh) * 2022-08-31 2023-03-17 沐曦科技(北京)有限公司 一种用于仿真的非标准总线协议的芯片验证装置

Also Published As

Publication number Publication date
WO1999032514A2 (fr) 1999-07-01
AU1918099A (en) 1999-07-12
KR20010033299A (ko) 2001-04-25
BR9813757A (pt) 2000-10-03
EP1044217A2 (fr) 2000-10-18
JP2001526063A (ja) 2001-12-18
WO1999032514A3 (fr) 1999-09-10
NZ503417A (en) 2002-12-20
AU765741B2 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
US5928884A (en) FHIT proteins and nucleic acids and methods based thereon
CA2304124A1 (fr) Proteine bim de type bci-2 et methodes pour l'utiliser
NZ277946A (en) Apoptosis modulating protein and nucleotide sequence compositions using bcl-2 homologs termed cdn-1, cdn-2 and cdn3
JPH09504959A (ja) 哺乳動物細胞周期蛋白質
WO2000012139A1 (fr) Genes regules par l'hypoxie
AU765741B2 (en) Sag: sensitive to apoptosis gene
WO1998040397A1 (fr) Proteines inhibitrices de bax
CA2296105A1 (fr) Nouvel inhibiteur de proliferation cellulaire
CA2290778A1 (fr) Molecules anti-apoptose de type fadd, procedes d'utilisation de ces molecules, compositions et procedes de preparation de ces compositions
AU728352B2 (en) BRCA1 associated protein (BAP-1) and uses therefor
AU733462B2 (en) CYP7 promoter-binding factors
WO1998005968A9 (fr) Proteine bap-1 associee a la brca1 et ses utilisations
WO1998039434A9 (fr) Procede et reactifs servant a moduler l'apoptose
US7256321B2 (en) Intracellular modulators of apoptopic cell death pathways
EP1007672B1 (fr) Glissieres a leucine induites par un glucocorticoide servant de modulateurs intracellulaires des mecanismes d'apoptose cellulaire
JP2002503466A (ja) 網膜芽細胞腫タンパク質複合体および網膜芽細胞腫相互作用タンパク質
CA2376382A1 (fr) Gene codant pour "nade" ou activateur de mort cellulaire associe a p75ntr et procede de son utilisation
MXPA00003201A (en) Sag:sensitive to apoptosis gene
CN100443501C (zh) 人骨髓基质细胞来源的线粒体转运蛋白分子及其编码序列和用途
AU752360B2 (en) Novel therapeutic molecules
US6605710B2 (en) Gene whose expression promotes differentiation of myeloid progenitor cells into neutrophils and/or monocytes/macrophages
ZA200101567B (en) Hypoxia regulated genes.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead